The pan-AKT inhibitor capivasertib, an orally bioavailable small-molecule inhibitor of all three AKT isoforms, has been newly approved by the Food and Drug Administration (FDA) for hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer, and might also be considered as a future therapeutic approach for HCC treatment [45]. The gene discussed is HR; the disease is breast cancer.